Navigation Links
Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Date:8/18/2008

S

RECONCILIATION OF NON-GAAP FINANCIAL DATA

For the Three Months For the Three Months

Ended Ended

Adjusted Net income June 30, 2008 June 30, 2007

($ in thousands except per

share data) Diluted Diluted

Net Income (Loss) Diluted EPS Net Income EPS Net Income EPS

Adjusted Amount 2,533,555 0.06 3,389,362 0.08

Adjustments

Non cash debt financing

costs (1) 353,646 0.01 347,837 0.01

Amount per consolidated

statement of operations 2,179,909 0.05 3,041,525 0.07

(1) Non cash debt financing costs for Q2 2008 includes amortization of

debt issuance costs of $99,517 and amortization of discount on

convertible redeemable preferred stock of $254,129; Non cash debt

financing costs for Q2 2007 includes amortization of debt issuance

costs of $58,680 amortization of debt discount of $289,157.

For the Six Months For the Six Months

Ended Ended

Adjusted Net income June 30, 2008 June 30, 2007

($ in thousands except per

share data) Diluted Diluted

Net Income (Loss) Diluted EPS Net Income EPS Net Income EPS

Adjusted Amount 3,885,230 0.08 4,400,581 0.10

Adjustments

Non cash debt financing

costs (2) 709,222 0.01 521,755 0.01

Amount per consolidated

statement of operations 3,176,008 0.07 3,878,826 0.09

(2) Non cash debt financing costs for the first half year 2008 includes

'/>"/>
SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... has granted to German life sciences entrepreneurs with ... commercialization of biotechnology (collectively, the "Optionee"), an option ... tumor vaccine technology (the "Technology"), including AEZS-120, the ... is ready to enter a Phase 1 clinical ...
(Date:7/28/2015)... , July 28, 2015 ... company utilizing its proprietary plant-based rhCollagen technology for ... has been appointed Senior Director of Business Development, ... http://photos.prnewswire.com/prnh/20150728/246955 ) , Ms. ... marketing, regulatory and business strategy. Prior to joining ...
(Date:7/27/2015)... THOUSAND OAKS, Calif. , July 27, 2015 /PRNewswire/ ... will report its second quarter financial results on Thursday, ... financial markets. The announcement will be followed by a ... PT. Participating in the call from Amgen will be ... officer, and other members of Amgen,s senior management team. ...
(Date:7/27/2015)... EDMONTON , July 27, 2015 /PRNewswire/ - Quest ... pharmaceutical company developing and commercializing products for the treatment ... Quest announces that it has closed a $1,000,000 ... private placement of 16,666,667 units of the Company at ... comprised of one common share and one common share ...
Breaking Biology Technology:Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Amgen Announces Webcast of 2015 Second Quarter Financial Results 2Quest PharmaTech Closes $1,000,000 Private Placement 2
... July 22, 2011 NeoStem, Inc. (NYSE Amex: ... today announced the closing of an underwritten public offering of ... unit consists of one share of common stock and a ... with a per share exercise price of $1.45. Lazard Capital ...
... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that ... in Europe for use in colorectal cancer. ... KRAS gene of colorectal cancer tissue that are predictive ... receptor (EGFR) antibody therapies. "By quickly ...
... #1 rated morning news program, The Today Show , ... that measures cellular aging.  The segment entitled How to ... tool for those interested in monitoring their health with biomarkers ... person,s biological age in comparison to their chronological age, giving ...
Cached Biology Technology:NeoStem Announces Closing of Public Offering for $16,500,000 in Gross Proceeds 2NeoStem Announces Closing of Public Offering for $16,500,000 in Gross Proceeds 3KRAS Diagnostic Test That Assists With Personalized Treatment of Colorectal Cancer Receives CE Mark 2KRAS Diagnostic Test That Assists With Personalized Treatment of Colorectal Cancer Receives CE Mark 3SpectraCell's Telomere Testing Goes Mainstream 2SpectraCell's Telomere Testing Goes Mainstream 3
(Date:7/2/2015)... July 2, 2015 Fingerprint Cards has ... FPC1145 and FPC1155 from the distributor World Peace Industrial Group ... distributors in Asia . Deliveries are planned ... will be used by smartphone manufacturers in Asia ... in the communicated revenue guidance of approximately 2,200 MSEK for ...
(Date:6/26/2015)... -- ATL Technology, LLC, a top provider of electromechanical contract ... solutions, headquartered in Springville, Utah , has ... corporation with locations in Santa Clara, ... ). This acquisition will incorporate MedConx,s manufacturing ... Technology,s existing facility in Costa Rica , ...
(Date:6/24/2015)... The biologics safety testing market is growing ... market include growth of the pharmaceutical and biological industries ... the years, the number of drug approvals in North ... FDA approved 225 drug applications and Health Canada approved ... accounted for 3,822 of the pharmaceutical and ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... new model built around biological data from electronic tags, ear ... indicates fishing on one side of the Atlantic influences the ... Atlantic Ocean have declined precipitously since 1950, according to the ... ONE . The model estimates the number of Atlantic ...
... behind counting fish in the ocean to measure their abundance ... NOAA Fisheries biologist Eric Prince, Ph.D., and eight other scientists ... change have added a new wrinkle to that science. ... journal Nature Climate Change , these scientists sound an ...
... HIV/AIDS prevention and treatment efforts are missing a major ... by simply adding low-cost care for the many other ... these same patients, according to a panel of disease ... American Society of Tropical Medicine and Hygiene (ASTMH). ...
Cached Biology News:New study provides comprehensive view of the status of Atlantic bluefin tuna 2New study provides comprehensive view of the status of Atlantic bluefin tuna 3Expanding dead zones shrinking tropical blue marlin habitat 2Expanding dead zones shrinking tropical blue marlin habitat 3Tropical disease experts report missed opportunity to transform global HIV/AIDS fight 2Tropical disease experts report missed opportunity to transform global HIV/AIDS fight 3Tropical disease experts report missed opportunity to transform global HIV/AIDS fight 4